This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
PKRA83 hydrochloride hydrate
Catalog No. T81445
Synonyms:
PKRA7 hydrochloride hydrate
PKRA83 hydrochloride hydrate, also known as PKRA7, is a potent prokineticin (PK2) antagonist that competes with PK2 for binding to its receptors, PKR1 and PKR2. It exhibits high inhibitory affinity with IC50 values of 5.0 nM for PKR1 and 8.2 nM for PKR2, displaying anticancer, anti-arthritis, and anti-angiogenic properties. Additionally, this compound is capable of crossing the blood-brain barrier [1] [2] [3].
All TargetMol products are for research or drug registration purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose in violation of laws and regulations.
PKRA83 hydrochloride hydrate, also known as PKRA7, is a potent prokineticin (PK2) antagonist that competes with PK2 for binding to its receptors, PKR1 and PKR2. It exhibits high inhibitory affinity with IC50 values of 5.0 nM for PKR1 and 8.2 nM for PKR2, displaying anticancer, anti-arthritis, and anti-angiogenic properties. Additionally, this compound is capable of crossing the blood-brain barrier [1] [2] [3].
In vitro
PKRA83 at a concentration of 1 µg/mL effectively reduces microvascular endothelial cell branching induced by PK2 in vitro [1].
In vivo
PKRA83 hydrochloride hydrate, administered at a dose of 20 mg/kg via intraperitoneal injection, demonstrated antitumor activity in a xenograft glioblastoma model [1]. Furthermore, when given at 15 mg/kg through intraperitoneal injection daily for two weeks, PKRA83 hydrochloride hydrate inhibited arthritis in mice with collagen-induced arthritis [2].
Synonyms
PKRA7 hydrochloride hydrate
Molecular Weight
N/A
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dose Conversion
You can also refer to dose conversion for different animals.
More
Method for preparing DMSO master liquid: mg
drug pre-dissolved in μL DMSO (Master liquid concentration
mg/mL),
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL PEG300, mix and clarify, next add μL
Tween 80,mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL Corn oil,mix and clarify.
Note:
Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculator
Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
bottom
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.